Skip to main content
. 2017 May 3;18(5):962. doi: 10.3390/ijms18050962
RAS Resistance-associated substitution
DAA Direct-acting antiviral
SMV/PEG-IFN/RBV Simeprevir/pegylated-interferon/ribavirin
DCV/ASV Daclatasvir/asunaprevir
CHC Chronic hepatitis C
HCV Hepatitis C virus
HCC Hepatocellular carcinoma
SVR Sustained viral response